[go: up one dir, main page]

UY33445A - Un régimen de dosificación, métodos para tratar el virus de la hepatitis c, composición farmacéutica, compuesta, compuestos anti-hcv y kit - Google Patents

Un régimen de dosificación, métodos para tratar el virus de la hepatitis c, composición farmacéutica, compuesta, compuestos anti-hcv y kit

Info

Publication number
UY33445A
UY33445A UY0001033445A UY33445A UY33445A UY 33445 A UY33445 A UY 33445A UY 0001033445 A UY0001033445 A UY 0001033445A UY 33445 A UY33445 A UY 33445A UY 33445 A UY33445 A UY 33445A
Authority
UY
Uruguay
Prior art keywords
methods
virus
kit
composite
pharmaceutical composition
Prior art date
Application number
UY0001033445A
Other languages
English (en)
Inventor
William E Delaney
William A Lee
David W Oldach
Rousseau Franck
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of UY33445A publication Critical patent/UY33445A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMBINACIONES DE MOLECULAS TERAPEUTICAS QUE RESULTAN DE UTILIDAD PARA TRATAR LA INFECCION POR EL VIRUS DE LA HEPATITIS C. LA PRESENTE INVENCION SE REFIERE A METODOS, USOS, REGIMENES DE DOSIFICACION Y COMPOSICIONES.
UY0001033445A 2010-06-10 2011-06-10 Un régimen de dosificación, métodos para tratar el virus de la hepatitis c, composición farmacéutica, compuesta, compuestos anti-hcv y kit UY33445A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35346010P 2010-06-10 2010-06-10

Publications (1)

Publication Number Publication Date
UY33445A true UY33445A (es) 2012-01-31

Family

ID=44343211

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033445A UY33445A (es) 2010-06-10 2011-06-10 Un régimen de dosificación, métodos para tratar el virus de la hepatitis c, composición farmacéutica, compuesta, compuestos anti-hcv y kit

Country Status (5)

Country Link
US (1) US20110306541A1 (es)
AR (1) AR084393A1 (es)
TW (1) TW201211047A (es)
UY (1) UY33445A (es)
WO (1) WO2011156757A1 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US7824851B2 (en) 2002-11-15 2010-11-02 Idenix Pharmaceuticals, Inc. 2′-branched nucleosides and Flaviviridae mutation
SI2430014T1 (sl) * 2009-05-13 2015-10-30 Gilead Pharmasset Llc Protivirusne spojine
CN105061534A (zh) 2010-09-22 2015-11-18 艾丽奥斯生物制药有限公司 取代的核苷酸类似物
TW201306841A (zh) 2010-12-20 2013-02-16 Gilead Sciences Inc 治療ｃ型肝炎病毒（ｈｃｖ）之方法
JP2014514295A (ja) 2011-03-31 2014-06-19 アイディニックス ファーマシューティカルズ インコーポレイテッド ウイルス感染の治療のための化合物および薬学的組成物
AR088441A1 (es) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
PE20141056A1 (es) * 2011-09-16 2014-09-05 Gilead Pharmasset Llc Metodos para el tratamiento de vhc
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
PH12014500832A1 (en) 2011-10-21 2022-12-02 Abbvie Inc Methods for treating hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
JP5677646B2 (ja) 2011-10-21 2015-02-25 アッヴィ・インコーポレイテッド Ｈｃｖの治療に使用するためのｄａａの（例えばａｂｔ−０７２もしくはａｂｔ−３３３との）併用治療
US8980865B2 (en) 2011-12-22 2015-03-17 Alios Biopharma, Inc. Substituted nucleotide analogs
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US8916538B2 (en) 2012-03-21 2014-12-23 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
EP2827876A4 (en) 2012-03-22 2015-10-28 Alios Biopharma Inc PHARMACEUTICAL COMBINATIONS WITH A THIONUCLEOTIDE ANALOG
US9109001B2 (en) 2012-05-22 2015-08-18 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphoramidate prodrugs for HCV infection
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
MX355708B (es) 2012-05-22 2018-04-27 Idenix Pharmaceuticals Llc Compuestos de d-aminoacidos para enfermedades del higado.
AP3545A (en) 2012-05-25 2016-01-14 Janssen Sciences Ireland Uc Uracyl spirooxetane nucleosides
US9056860B2 (en) * 2012-06-05 2015-06-16 Gilead Pharmasset Llc Synthesis of antiviral compound
US8969588B2 (en) * 2012-06-05 2015-03-03 Gilead Pharmasset Llc Solid forms of an antiviral compound
US9192621B2 (en) 2012-09-27 2015-11-24 Idenix Pharmaceuticals Llc Esters and malonates of SATE prodrugs
EP2906579B1 (en) 2012-10-08 2018-04-18 Idenix Pharmaceuticals LLC. 2'-chloro nucleoside analogs for hcv infection
WO2014066239A1 (en) 2012-10-22 2014-05-01 Idenix Pharmaceuticals, Inc. 2',4'-bridged nucleosides for hcv infection
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
MX351816B (es) * 2013-01-31 2017-10-30 Gilead Pharmasset Llc Formulacion de combinacion de dos compuestos antivirales.
TW201446286A (zh) * 2013-01-31 2014-12-16 Gilead Pharmasset Llc 抗病毒化合物之固態分散調製劑
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
EP2970358B1 (en) 2013-03-04 2021-06-30 Idenix Pharmaceuticals LLC 3'-deoxy nucleosides for the treatment of hcv
US20140271547A1 (en) 2013-03-13 2014-09-18 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
PT3038601T (pt) 2013-08-27 2020-06-30 Gilead Pharmasset Llc Formulação combinada de dois compostos antivirais
US10202411B2 (en) 2014-04-16 2019-02-12 Idenix Pharmaceuticals Llc 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
CN104513147B (zh) * 2014-11-20 2016-05-11 上海众强药业有限公司 芴乙酮衍生物的制备方法
HRP20211456T1 (hr) 2014-12-26 2021-12-24 Emory University Protuvirusni derivati n4-hidroksicitidina
WO2016145269A1 (en) * 2015-03-12 2016-09-15 Teva Pharmaceuticals International Gmbh Solid state forms ledipasvir and processes for preparation of ledipasvir
CN105237516B (zh) * 2015-10-13 2018-01-02 厦门市蔚嘉化学科技有限公司 一种雷迪帕韦的制备方法
CN105237517B (zh) * 2015-10-30 2017-10-27 南京正大天晴制药有限公司 结晶的雷迪帕韦化合物及其制备方法
CN105646208B (zh) * 2016-02-24 2018-10-16 潍坊晶润化工股份有限公司 丙酮酸甲酯的制备方法
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University ALCYNE-CONTAINING NUCLEOTIDES AND NUCLEOSIDES THERAPEUTIC COMPOSITIONS AND USES THEREOF
CN106432197B (zh) * 2016-09-07 2019-12-10 上海众强药业有限公司 一种雷迪帕韦中间体单对甲苯磺酸盐、其晶型及其制备方法
ES2995458T3 (en) 2017-12-07 2025-02-10 Univ Emory N4-hydroxycytidine derivative and anti-viral uses related thereto
CN111542939A (zh) 2018-01-23 2020-08-14 富士胶片株式会社 有机半导体元件、有机半导体组合物、有机半导体膜、有机半导体膜的制造方法及用于这些的聚合物
US11378965B2 (en) 2018-11-15 2022-07-05 Toyota Research Institute, Inc. Systems and methods for controlling a vehicle based on determined complexity of contextual environment
EP4341266A1 (en) 2021-05-21 2024-03-27 Gilead Sciences, Inc. Pentacyclic derivatives as zika virus inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068162A2 (en) * 2002-02-14 2003-08-21 Pharmasset Ltd. Modified fluorinated nucleoside analogues
WO2004002940A1 (en) * 2002-07-01 2004-01-08 Pharmacia & Upjohn Company Inhibitors of hcv ns5b polymerase
ES2531315T3 (es) * 2006-07-07 2015-03-12 Gilead Sciences Inc Compuestos de fosfinato antivíricos
AU2007269614B2 (en) * 2006-07-07 2011-09-08 Gilead Sciences, Inc. Novel pyridazine compound and use thereof
US7842672B2 (en) * 2006-07-07 2010-11-30 Gilead Sciences, Inc. Phosphonate inhibitors of HCV
US20110150836A1 (en) * 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection

Also Published As

Publication number Publication date
AR084393A1 (es) 2013-05-15
WO2011156757A1 (en) 2011-12-15
TW201211047A (en) 2012-03-16
US20110306541A1 (en) 2011-12-15

Similar Documents

Publication Publication Date Title
UY33445A (es) Un régimen de dosificación, métodos para tratar el virus de la hepatitis c, composición farmacéutica, compuesta, compuestos anti-hcv y kit
BR112014006324B8 (pt) composição e seu uso para o tratamento de hcv
AR084237A1 (es) Metodos para tratar virus de hepatitis c (hcv), composicion
GT201500021A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
GT201500312A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b
BR112015009624A2 (pt) inibidores de tirosina cinase de bruton
UY33897A (es) Inhibidores del virus de la hepatitis c
CR20140410A (es) Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento
GT201400009A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk
GT201200257A (es) Composiciones sólidas
CL2017002082A1 (es) Nuevas proteínas especificas para pioverdina y pioquelina
BR112014010290B8 (pt) Composição farmacêutica na forma de dispersão sólida de ativos específicos em polímeros específicos e uso da composição farmacêutica
HN2011003403A (es) Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
CL2014000394A1 (es) Uso de compuestos fenil-benzofuran-sulfamido sustituidos para el tratamiento del virus de la hepatitis c (hcv); y composicion farmaceutica que comprende a estos compuestos fenil-benzofuran-sulfamido sustituidos.
CO2017007874A2 (es) Composiciones y métodos para metabolismo muscular mejorado
DOP2010000400A (es) 7-sulfanilmetil-,7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
BR112013020359B8 (pt) Colágeno gelificável e meios para a sua provisão
EA201590782A1 (ru) Оксирановые амины
CO7170180A2 (es) Composición farmacéutica inyectable de dexketoprofeno y tramadol
MX2014010749A (es) Composicion ginecologica para tratar la vestibulitis vulvar.
BR112017019758A2 (pt) tratamento combinado com um agonista tlr7 e um inibidor de conjunto de capsídeo de hbv
CU20100260A7 (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
CR20140273A (es) Composiciones y métodos para tratar el virus de la hepatitis c
CR20150060A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200807